Get the Stockscreener App
359.58
0.16%
-0.58
United Therapeutics Corp stock is traded at $359.58, with a volume of 706.51K.
It is down -0.16% in the last 24 hours and down -1.30% over the past month.
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
See More
Previous Close:
$360.16
Open:
$359.5
24h Volume:
706.51K
Relative Volume:
2.15
Market Cap:
$16.05B
Revenue:
$2.76B
Net Income/Loss:
$1.11B
P/E Ratio:
19.81
EPS:
18.15
Net Cash Flow:
$898.10M
1W Performance:
-0.62%
1M Performance:
-1.30%
6M Performance:
+16.38%
1Y Performance:
+59.45%
1-Day Range:
$357.99
$363.90
1-Week Range:
$350.60
$383.00
52-Week Range:
$208.62
$417.81
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Industry
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
359.58 | 16.05B | 2.76B | 1.11B | 898.10M | 22.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
Insider Sell: Louis Sullivan Sells 26,209 Shares of United Thera - GuruFocus.com
United Therapeutics Co. (NASDAQ:UTHR) Director Sells $9,781,722.98 in Stock - MarketBeat
United Therapeutics director sells shares worth $9.78 million - Investing.com
United Therapeutics president and COO sells $3.7 million in stock - Investing.com India
United Therapeutics (NASDAQ:UTHR) Trading Down 4.4%Here's Why - MarketBeat
United Therapeutics 'no longer pursuing' nearly 350 acres in Hackett Hill area - The Union Leader
United Therapeutics president and COO sells $3.7 million in stock By Investing.com - Investing.com UK
United Therapeutics Makes History: First-Ever Genetically Modified Pig Kidney Transplant Success - StockTitan
United Therapeutics cancels plans to buy Hackett Hill property from Manchester - New Hampshire Business Review
Franklin Resources Inc. Grows Stake in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Tidal Investments LLC Acquires 2,803 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Lord Abbett & CO. LLC Buys 46,170 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Oddo BHF Asset Management Sas Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Geode Capital Management LLC Purchases 45,566 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Tri Ri Asset Management Corp Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
iA Global Asset Management Inc. Lowers Stock Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics president sells $3.45 million in stock By Investing.com - Investing.com Canada
United Therapeutics president sells $3.45 million in stock - Investing.com
Brophy Wealth Management LLC Invests $809,000 in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case - Simply Wall St
United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Worldquant Millennium Advisors LLC - MarketBeat
State Street Corp Decreases Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Dorsey Wright & Associates Purchases New Holdings in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) EVP Sells $2,882,649.00 in Stock - MarketBeat
United Therapeutics' EVP sells $2.88 million in stock - Investing.com India
United Therapeutics' EVP sells $2.88 million in stock By Investing.com - Investing.com Canada
United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by Chevy Chase Trust Holdings LLC - MarketBeat
Janus Henderson Group PLC Acquires 50,409 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp Sells 1,531 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Parkman Healthcare Partners LLC - MarketBeat
PDT Partners LLC Reduces Stake in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Edgestream Partners L.P. Buys New Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $76.21 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
PH-ILD Pipeline 2024: Clinical Trials Assessment, FDA - openPR
45,266 Shares in United Therapeutics Co. (NASDAQ:UTHR) Acquired by Erste Asset Management GmbH - MarketBeat
Zurcher Kantonalbank Zurich Cantonalbank Has $10.44 Million Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
BNP Paribas Financial Markets Has $12.25 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
True Wealth Design LLC Sells 3,274 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Cerity Partners LLC Acquires 4,005 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Fmr LLC Acquires 314,004 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Bank of Montreal Can - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Martingale Asset Management L P - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Holdings Trimmed by Crawford Fund Management LLC - MarketBeat
The 3.8% return this week takes United Therapeutics' (NASDAQ:UTHR) shareholders five-year gains to 314% - Yahoo Finance
United Therapeutics Co. (NASDAQ:UTHR) Shares Bought by Bridgewater Associates LP - MarketBeat
Glenmede Trust Co. NA Boosts Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics president sells shares worth $3.73 million By Investing.com - Investing.com Nigeria
Dai ichi Life Insurance Company Ltd Sells 1,412 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Insider Selling: United Therapeutics Co. (NASDAQ:UTHR) COO Sells 10,000 Shares of Stock - MarketBeat
United Therapeutics president sells shares worth $3.73 million - Investing.com
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
United Therapeutics Corp Stock (UTHR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| SULLIVAN LOUIS W | Director |
Dec 18 '24 |
Option Exercise |
175.43 |
15,000 |
2,631,450 |
31,260 |
| SULLIVAN LOUIS W | Director |
Dec 18 '24 |
Sale |
373.22 |
26,209 |
9,781,715 |
5,051 |
0.43%
1.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):